Table 1.
Recommendations for each guideline in active surveillance.
| Guideline | Inclusion Criteria | Strength of Recommendation |
||||
|---|---|---|---|---|---|---|
| Clinical Stage | Gleason Score | Cancer Volume | PSA (ng/mL) | PSA Density (ng/mL/cm3) | ||
| AUA [8] | ≦T2 | ≦6 | - | <20 | - | strong |
| ≦T2 | 3 + 4 | low % of pattern 4; <50% of total cores positive |
<10 | low | strong | |
| EAU [9] | ≦T2a | ≦6 | - | <10 | - | strong |
| ≦T2a | 3 + 4 | <10% pattern 4; ≤3 cores positive; and ≤50% core involvement per core |
<10 | - | weak | |
| NCCN [10] | ≦T2a | ≦6 | - | <20 | ≦0.15 | - |
| ≦T2a | 3 + 4 | low % of pattern 4; <50% of total cores positive |
<10 | low | - | |
| JUA [17] | ≦T2 | ≦6 | ≦2 | <10 | <0.2 | grade B |
| ≦T2 | 3 + 4 | ≦2 | <10 | <0.2 | weak | |
PSA, prostate-specific antigen; AUA, American Urological Association; EAU, European Association of Urology; NCCN, National Comprehensive Cancer Network; JUA, Japanese Urological Association.